Zemlikafusp alfa

泽姆卡芙普α

Report date: 2026/04/17 20:02:02

Base Information

Drug NameZemlikafusp alfa
Drug Alias NameTetra-specific ANKETTetra-specific NK cell engaging antibody (Innate Pharma)IPH-6501IPH-65
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Tetraspecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionNatural cytotoxicity triggering receptor 1 agonistsFCGR3A (CD16a) NK-cell engagersAnti-CD20 +[4] 
TargetsNatural cytotoxicity triggering receptor 1Low affinity immunoglobulin gamma Fc region receptor III-AB-lymphocyte antigen CD20 +[4] 
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesInnate Pharma SA
China Registration ClassN/A

Develop Information

Active CompaniesInnate Pharma SA
Inactive CompaniesInnate Pharma
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Inactive IndicationsLymphoma, Non-HodgkinNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A